The kinin system: suggestions to broaden some prevailing concepts

https://doi.org/10.1016/S1567-5769(02)00166-2Get rights and content

Abstract

The existence and importance of the kallikrein–kinin–kininase system, especially in the circulation, has taken over three-quarters of a century to be established. Finding the multiple components derived from renin–angiotensin and their functions stretched over a century [Erdös EG. Perspectives on the early history of angiotensin-converting enzyme—recent follow-ups. In: Giles TD, editor. Angiotensin-converting enzyme (ACE): clinical and experimental insights. Fort Lee: Health Care Communications; 2001, p. 3–16]. Although the discoveries were made independently, it was shown in 1970 that the angiotensin I-converting enzyme (ACE) is identical with kininase II, previously discovered by us, thus, a single protein can regulate either the activation or inactivation of the two peptide products. It followed that inhibitors of ACE can affect both processes [Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1–80].

After being engaged for a long time in characterizing the metabolism of various bio-active peptides, we, as well as others, noticed that the effect of ACE inhibitors go beyond simply blocking angiotensin (Ang) II release and bradykinin (BK) inactivation by the enzyme [Kaplan AP, Joseph K, Silverberg M. J Allergy Clin Immunol 2002:109(2):195–209; Yamada K, Erdös EG. Kidney Int 1982;22:331–1]. It also became apparent to us that in the complex multistep reactions needed to activate the kallikrein–kinin system, there should be some shortcuts—shunts—to accelerate and simplify important processes. Thus, some basic tenets developed after decades of intensive laboratory investigations—and by now generally accepted—can be challenged. For example, it should be considered that the activities of BK and Lys BK (kallidin) can be substantially different, and that sequentially linked reactions, starting with prokallikrein activation and leading to kinin release from kininogen and inhibition of kininases, may be only one way to activate kinin receptors. A summary of some suggested alterations on prevailing concepts is given below.

Section snippets

Acknowledgements

These studies were supported in part by NIH-National Heart, Lung and Blood Institute grants #HL36473 and #HL58118. We are grateful to Ms. Sara Blaszczak for editorial assistance.

References (30)

  • E. Schröder

    Structure–activity relationships of kinins

  • F. Marceau et al.

    The B1 receptors for kinins

    Pharmacol. Rev.

    (1998)
  • B. Rubin et al.

    SQ14,225 (d-3-mercapto-2-methylpropanoyl-l-proline), a novel orally active inhibitor of angiotensin I-converting enzyme

    J. Pharmacol. Exp. Ther.

    (1978)
  • W. Auch-Schwelk et al.

    ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin

    Cardiovasc. Res.

    (1993)
  • E.G. Erdös

    Perspectives on the early history of angiotensin-converting enzyme—recent follow-ups

  • Cited by (19)

    • Kininases

      2018, Encyclopedia of Endocrine Diseases
    • Characterization of the kallikrein-kinin system during the bovine ovulation process

      2011, Peptides
      Citation Excerpt :

      The kallikrein–kinin system (KKS) is an important mediator of inflammatory responses acting on vasodilatation, activation and inactivation of proteases, stimulation of prostaglandin biosynthesis as well as induction of smooth muscle contractility [3,24]. Kininogen (KNG) is a precursor protein of the KKS; plasma kallikrein uses KNG as a substrate to generate bradykinin while tissue kallikrein liberates kallidin that is cleaved to the bradykinin [3,11]. Bradykinin is a nonapeptide kinin, the main mediator of KKS responses [3,8].

    • Structure and Function of the Heart

      2011, Pediatric Critical Care: Expert Consult Premium Edition
    • Structure and Function of the Heart

      2011, Pediatric Critical Care
    • Carboxypeptidase M and kinin B1 receptors interact to facilitate efficient B1 signaling from B2 agonists

      2008, Journal of Biological Chemistry
      Citation Excerpt :

      Although interactions between peptide receptors and related peptidases have not been extensively studied, recent evidence indicates that ACE and B2 kinin receptor do interact on the cell surface (44, 45). Because ACE readily inactivates bradykinin, it was previously thought that ACE inhibitors enhance B2R signaling solely by blocking degradation of the B2 agonist (46). However, several reports provide evidence that ACE inhibitors potentiate/resensitize B2R signaling apart from their ability to block bradykinin degradation (e.g. with ACE-resistant B2 agonists) (47).

    • Kinins and Endothelin

      2008, Seldin and Giebisch's The Kidney
    View all citing articles on Scopus
    View full text